Literature DB >> 24519506

Accidental injections of dexamethasone intravitreal implant (Ozurdex) into the crystalline lens.

Javier Coca-Robinot1, Bruno Casco-Silva, Felix Armadá-Maresca, Jesús García-Martínez.   

Abstract

PURPOSE: To describe the side effects and management after inadvertent injection of a dexamethasone implant (Ozurdex) into the crystalline lens.
METHODS: Two case reports.
RESULTS: Two patients with macular edema due to unilateral retinal vein occlusion were scheduled for an intravitreal injection of Ozurdex. During the procedure, the implant was accidentally injected into the crystalline lens. Both patients developed cataracts during the course of several weeks and in both there was an intraocular pressure (IOP) increase, which required treatment with topical hypotensives. Macular edema improved only slightly. Cataract surgery with uneventful removal of the implant was performed 3 (case 1) and 6 months (case 2) after the injection.
CONCLUSIONS: After inadvertent injection of Ozurdex into the crystalline lens, cataract surgery with removal of the implant should be performed as soon as possible in order to avoid IOP increase and so that the underlying condition may be treated adequately.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24519506     DOI: 10.5301/ejo.5000439

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   2.597


  19 in total

1.  Effect of Prior Anti-VEGF Injections on the Risk of Retained Lens Fragments and Endophthalmitis after Cataract Surgery in the Elderly.

Authors:  Paul Hahn; Arseniy P Yashkin; Frank A Sloan
Journal:  Ophthalmology       Date:  2015-08-13       Impact factor: 12.079

2.  Retinal injury following intravitreal injection of a dexamethasone implant in a vitrectomized eye.

Authors:  Seung Min Lee; Jae Woo Jung; Sung Who Park; Ji Eun Lee; Ik Soo Byon
Journal:  Int J Ophthalmol       Date:  2017-06-18       Impact factor: 1.779

3.  Rate of intraoperative complications during cataract surgery following intravitreal injections.

Authors:  P Hahn; K Jiramongkolchai; S Stinnett; M Daluvoy; T Kim
Journal:  Eye (Lond)       Date:  2016-05-27       Impact factor: 3.775

4.  Intralenticular Ozurdex® - One Year Later.

Authors:  Kathleen A Regan; Charles R Blake; Zachary L Lukowski; Siva S R Iyer
Journal:  Case Rep Ophthalmol       Date:  2017-12-21

Review 5.  Perspective on the role of Ozurdex (dexamethasone intravitreal implant) in the management of diabetic macular oedema.

Authors:  Hemal Mehta; Mark Gillies; Samantha Fraser-Bell
Journal:  Ther Adv Chronic Dis       Date:  2015-09       Impact factor: 5.091

6.  Management of foveal adhesion of a dexamethasone implant.

Authors:  Yuji Itoh; Sunil K Srivastava; Justis P Ehlers
Journal:  Acta Ophthalmol       Date:  2015-10-07       Impact factor: 3.761

7.  Intracrystalline Ozurdex®: therapeutic effect maintained for 18 months.

Authors:  Rodrigo Clemente-Tomás; Delia Hernández-Pérez; Paulina Neira-Ibáñez; Francisco Farías-Rozas; Raúl Torrecillas-Picazo; Vanesa Osorio-Alayo; Antonio M Duch-Samper
Journal:  Int Ophthalmol       Date:  2017-11-30       Impact factor: 2.031

8.  Morphometric assessment of normal human ciliary body using ultrasound biomicroscopy.

Authors:  Yoshifumi Okamoto; Fumiki Okamoto; Shinichiro Nakano; Tetsuro Oshika
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-10-03       Impact factor: 3.117

Review 9.  Dexamethasone intravitreal implant in the treatment of diabetic macular edema.

Authors:  Pravin U Dugel; Francesco Bandello; Anat Loewenstein
Journal:  Clin Ophthalmol       Date:  2015-07-16

10.  Intralenticular Sustained-Release Dexamethasone Implant: Is It Still Effective on Macular Edema?

Authors:  Mehmet Ali Sekeroglu; Mustafa Alpaslan Anayol; Fatih Koc; Hakan Tirhis; Seyhan Sonar Ozkan; Pelin Yilmazbas
Journal:  Case Rep Ophthalmol       Date:  2016-02-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.